Blog
NPs/PAs Provide One-Quarter of Healthcare Visits in the US
As the rate of growth of nurse practitioners (NPs) and physician assistants (PAs) in the US continues to rise rapidly, research shows that the share of healthcare visits provided by NPs and PAs has increased by 11% since 2013. According to the latest data, NPs and PAs...
Dermalorian™ Podcast: Can You Make the Diagnosis?
DERM 2023 was built around the theme of Stranger Dx™, and DERM Faculty member and DEF Advisory Council member Wendy Cantrell, DNP certainly brought a case to fit the theme. In this episode of the Dermalorian™ Podcast from the DEF, (SCROLL DOWN FOR LINKS TO EACH...
Galderma Submits BLAs for Nemolizumab for PN and AD
Galderma has submitted Biologics License Applications (BLAs) for nemolizumab for the treatment of prurigo nodularis (PN) and for moderate to severe atopic dermatitis (AD) in adolescents and adults. Nemolizumab is a first-in-class investigational monoclonal antibody...
Dermavant Submits sNDA for VTAMA for Topical Treatment of AD in Adults and Children
Dermavant Sciences has submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA for Vtama® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. VTAMA cream, 1% is currently FDA-approved...
Study Identifies Significant Costs for Individuals with Vitiligo
By Joe Gorelick, MSN, FNP-C Patients with vitiligo incur significantly higher healthcare costs than people without the skin condition, a new study published in Journal of Investigative Dermatology shows. In addition to direct costs that may be associated with managing...
Individuality a Key Aspect of Aesthetic Treatment, Allergan Report Says
By Joe Gorelick, MSN, FNP-C Individuality drives the definition of beauty for nearly three-quarters of Americans participating in a comprehensive survey by Allergan Aesthetics, an AbbVie. "Decoding the Future of Aesthetic Individuality" also reveals that 90% of...
Novel Topical Shows Promise for Androgenetic Alopecia in Phase 2a
A new, topical small molecule drug candidate shows promise for the treatment of androgenetic alopecia, having performed well in phase 2a clinical trials. TDM-105795 from Technoderma Medicines, Inc. is potent thyromimetic that has poor systemic absorption following...
CMS Issues Permanent J-Code for Ycanth
The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Ycanth™, which is the only FDA-approved treatment for molluscum contagiosum. Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for Ycanth...
HPV Awareness Week Shines Light on Cancers Associated with HPV Infections
By Joe Gorelick, MSN, FNP-C STDs, including HPV, are common presentations in the dermatology clinic. And the US is in the midst of an epidemic of STDs, noted dermatologist Ted Rosen, MD, at the DEF Essential Resource Meeting 2023 (DERM2023) NP and PA CME conference in...
Registration Now Open for DERM2024
UPDATE: Register before February 29 to take advantage of discounted registration for dermatology NPs, PAs, and Nurses. See details here. The Dermatology Education Foundation (DEF) today announced that registration is now open for the DEF Essential Resource Meeting...
